Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression
Kumaran Mudaliar, Michael T. Tetzlaff, Madeleine Duvic, et al.
Human Pathology (2015) Vol. 50, pp. 79-89
Closed Access | Times Cited: 19

Showing 19 citing articles:

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Mario E. Lacouture, V. Sibaud
American Journal of Clinical Dermatology (2018) Vol. 19, Iss. S1, pp. 31-39
Open Access | Times Cited: 293
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry, Michael T. Tetzlaff, Priyadharsini Nagarajan, et al.
Journal of Cutaneous Pathology (2016) Vol. 44, Iss. 2, pp. 158-176
Open Access | Times Cited: 214
Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma
T M Reed, Steven Rivera, Craig M. Fisher, et al.
Journal of Cutaneous Pathology (2025)
Closed Access
Characterization of glycolysis-related gene expression in malignant melanoma
A. Koch, Eva Vanessa Ebert, Tatjana Seitz, et al.
Pathology - Research and Practice (2019) Vol. 216, Iss. 1, pp. 152752-152752
Closed Access | Times Cited: 32
Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study
Christina Boull, Samantha Gardeen, Talal Abdali, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 6, pp. 1554-1561
Closed Access | Times Cited: 29
Cutaneous toxicities of new treatments for melanoma
Aram Boada, Cristina Carrera, Sònia Segura, et al.
Clinical & Translational Oncology (2018) Vol. 20, Iss. 11, pp. 1373-1384
Closed Access | Times Cited: 27
Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report
Karen Lam, Gregory A. Gates, Daniel Q. Bach, et al.
Case Reports in Dermatology (2024) Vol. 16, Iss. 1, pp. 133-139
Open Access | Times Cited: 2
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
Subashini Sharon Gnanendran, Lauren M. Turner, James Miller, et al.
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 4
Closed Access | Times Cited: 15
Lentiviral vector‑mediated IL‑9 overexpression stimulates cell proliferation by targeting c‑myc and cyclin D1 in colitis‑associated cancer
Linglin Tian, Yuan Li, Ruqi Chang, et al.
Oncology Letters (2018)
Open Access | Times Cited: 16
Drug-induced eruptive melanocytic nevi
Gino Antonio Vena, Maria Concetta Fargnoli, Nicoletta Cassano, et al.
Expert Opinion on Drug Metabolism & Toxicology (2016) Vol. 13, Iss. 3, pp. 293-300
Closed Access | Times Cited: 14
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
Shakuntala H. Mauzo, Michael T. Tetzlaff, Kelly C. Nelson, et al.
International Journal of Dermatology (2017) Vol. 58, Iss. 9, pp. 1045-1052
Closed Access | Times Cited: 13
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib
Vishwas Parekh, Joseph F. Sobanko, Christopher J. Miller, et al.
Journal of Cutaneous Pathology (2018) Vol. 46, Iss. 3, pp. 190-194
Open Access | Times Cited: 6
Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy
Riyad N. H. Seervai, Woo Cheal Cho, Emily Y. Chu, et al.
Journal of Cutaneous Pathology (2021) Vol. 49, Iss. 1, pp. 61-81
Open Access | Times Cited: 6
Traumatized and Recurrent Melanocytic Nevi

American Registry of PathologyArlington, Virginia eBooks (2024), pp. 59-68
Closed Access
New Discoveries and Updates on Cutaneous Adverse Drug Reactions Presented at the 24th World Congress of Dermatology, Milan, Italy, 2019
Felix Chan, Neil H. Shear, Nidhi Shah, et al.
Drug Safety (2019) Vol. 43, Iss. 2, pp. 179-187
Closed Access | Times Cited: 3
Dermatologic Toxicities to Melanoma Targeted Therapies
Jonathan L. Curry, Ana M. Ciurea, Priyadharsini Nagarajan, et al.
Springer eBooks (2016), pp. 267-277
Closed Access | Times Cited: 1
New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma
Panagiotis Diamantopoulos, Eleftheria Lakiotaki, Georgios Kyriakakis, et al.
Melanoma Research (2019) Vol. 30, Iss. 2, pp. 206-208
Closed Access | Times Cited: 1
The Many Faces of the Paradoxical Response to BRAF Inhibitors
Rastine Merat
Clinical skin cancer (2017) Vol. 2, Iss. 1-2, pp. 39-43
Closed Access
Persistent/Recurrent Melanocytic Nevi, Traumatized Nevi, and Nevi Changing Under Therapy
Maija Kiuru, Pedram Gerami, Klaus J. Busam
Elsevier eBooks (2018), pp. 101-111
Closed Access
Page 1

Scroll to top